임상시험용 물품 시장 규모, 점유율 및 동향 분석 보고서 : 단계별, 서비스별, 제품별, 치료 영역별, 지역별 및 부문별 예측(2026-2033년)

Clinical Trial Supplies Market Summary

The global clinical trial supplies market size was estimated at USD 5.7 billion in 2025 and is projected to reach USD 10.7 billion by 2033, growing at a CAGR of 8.4% from 2026 to 2033. The market growth is driven by increasing R&D investments, the rising prevalence of chronic diseases, and the globalization of clinical trials.

Some other factors contributing to the market are the expansion of biologics and personalized medicine, increased demand for complex supply chain solutions, including temperature-sensitive logistics and just-in-time delivery models. Furthermore, growing outsourcing trends among pharmaceutical and biotech companies to specialized supply providers further boost the market expansion.

Growing outsourcing trends among pharmaceutical and biotech companies to specialized supply providers drive the market expansion. Besides, increasing focus on biologics and personalized medicine is accelerating the clinical trial supplies industry, requiring specialized supply chain solutions. Biologic drugs, such as monoclonal antibodies, cell therapies, and gene therapies, require highly controlled storage and transportation conditions, including cold chain logistics. As these treatments become more prominent, supply chain providers are strengthening their capabilities to efficiently handle temperature-sensitive materials.

Moreover, the rise of personalized medicine, which customizes treatments based on genetic profiles, has increased the demand for just-in-time (JIT) manufacturing and delivery models. These approaches minimize waste, reduce costs, and ensure that patient-specific drugs reach clinical sites efficiently. Therefore, pharmaceutical companies collaborate with specialized logistics providers to streamline operations and maintain product integrity.

The growing adoption of decentralized clinical trials (DCTs) further enhances the need for flexible supply chain strategies, supporting the broader market expansion by improving accessibility and efficiency in trial execution. Most clinical trials are currently being conducted in developing economies. The increasing cost of clinical trials and complications in the recruitment of patients have encouraged biopharmaceutical companies to outsource clinical trials to regions such as the Asia Pacific, Latin America, Central & Eastern Europe, and the Middle East. Disease variation in developing economies further aids biopharmaceutical companies in performing clinical trials on rare diseases. Asia Pacific also provides more significant economic benefits to biopharmaceutical companies, as governments in Singapore and China allocate funds to promote biomedical research. In Latin America, patient recruitment is easy due to reduced language barriers, which can help obtain informed consent easily, resulting in a faster clinical trial process.

Furthermore, the global clinical trial supplies industry is driven by increasing R&D investments in drug development and the rising prevalence of chronic diseases. Pharmaceutical and biotechnology companies are allocating higher budgets to clinical trials, driven by the growing need for novel therapeutics across oncology, cardiovascular, and rare diseases. This has led to an increase in the number and complexity of clinical trials, requiring efficient supply chain management.

In addition, the rise in chronic diseases among aging populations and lifestyle changes has expanded the demand for clinical trials, further propelling the need for reliable supply solutions. As a result, clinical trial supply providers are investing in advanced logistics, temperature-controlled storage, and real-time monitoring technologies to ensure the integrity of trial materials. The growing regulatory focus on Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) also imposes robust supply chain solutions to ensure compliance, further fueling the market growth. Thus, the increasing complexity of clinical trials is prompting pharmaceutical and biotechnology companies to outsource their supply chain management to specialized clinical trial supply providers. Outsourcing allows sponsors to utilize the expertise of third-party logistics providers, contract manufacturing organizations (CMOs), and contract research organizations (CROs) that offer specialized solutions for investigational drug distribution, packaging, and regulatory compliance. By partnering with specialized vendors, companies can optimize costs, streamline operations, and mitigate risks associated with supply chain disruptions. Thus, the rising adoption of flexible outsourcing models, including functional service provider (FSP) partnerships and end-to-end supply chain solutions, further accelerates the market growth. As clinical trials expand into emerging markets and decentralized models, there is a rising demand for specialized logistics partners with global reach and regulatory expertise.

Global Clinical Trial Supplies Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical trial supplies market based on product, service, phase, therapeutic area, and region:

• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Manufacturing
• Storage & Distribution
  • Cold Chain
  • Non-cold Chain
• Supply Chain Management
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical
• Biologics
• Medical device
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• CNS Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Disorders
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Phase
  • 1.2.2. Service
  • 1.2.3. Product
  • 1.2.4. Therapeutic Area
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Clinical Trial Supplies Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expansion of Clinical Trials Sites
    • 3.2.1.2. Growing R&D in Biologics and Biosimilars
    • 3.2.1.3. Advancements in Supply Chain Technology
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of Stringent Regulatory Policies
    • 3.2.2.2. High Possibility of Counterfeiting Drugs
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Clinical Trial Supplies Market: Phase Estimates & Trend Analysis

• 4.1. Clinical Trial Supplies Market, By Phase: Segment Dashboard
• 4.2. Clinical Trial Supplies Market, By Phase: Movement Analysis
• 4.3. Clinical Trial Supplies Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Trial Supplies Market: Service Estimates & Trend Analysis

• 5.1. Clinical Trial Supplies Market, By Service: Segment Dashboard
• 5.2. Clinical Trial Supplies Market, By Service: Movement Analysis
• 5.3. Clinical Trial Supplies Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Manufacturing
  • 5.4.1. Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Storage & Distribution
  • 5.5.1. Storage & Distribution Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Cold Chain
    • 5.5.2.1. Cold Chain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Non-cold Chain
    • 5.5.3.1. Non-Cold Chain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Supply Chain Management
  • 5.6.1. Supply Chain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Trial Supplies Market: Product Estimates & Trend Analysis

• 6.1. Clinical Trial Supplies Market, By Product: Segment Dashboard
• 6.2. Clinical Trial Supplies Market, By Product: Movement Analysis
• 6.3. Clinical Trial Supplies Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 6.4. Pharmaceutical
  • 6.4.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biologics
  • 6.5.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Medical Device
  • 6.6.1. Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Trial Supplies Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Clinical Trial Supplies Market, By Therapeutic Area: Segment Dashboard
• 7.2. Clinical Trial Supplies Market, By Therapeutic Area: Movement Analysis
• 7.3. Clinical Trial Supplies Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. CNS Diseases
  • 7.5.1. CNS Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Cardiovascular Diseases
  • 7.6.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Infectious Diseases
  • 7.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Metabolic Disorders
  • 7.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Clinical Trial Supplies Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Almac Group
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Biocair
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Catalent Inc.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. KLIFO
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Movianto
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. PCI Pharma Services
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Sharp Services, LLC
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Thermo Fischer Scientific Inc.
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. United Parcel Service of America, Inc (UPS Healthcare)
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Parexel International Corporation
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives